ライフサイエンスコーパス: vitreous hemorrhage

1 ntravitreous injection of Vitrase for severe vitreous hemorrhage.

2 ed with patient sex, age, or the presence of vitreous hemorrhage.

3 nd safe modalities for treatment of diabetic vitreous hemorrhage.

4 viable treatment approaches for PDR-related vitreous hemorrhage.

5 of vision in his left eye caused by a dense vitreous hemorrhage.

6 rectomy, central-involving macular edema, or vitreous hemorrhage.

7 r, inferior pre-retinal hemorrhage, and mild vitreous hemorrhage.

8 dates, and the development of a self-limited vitreous hemorrhage.

9 clearing was associated with the density of vitreous hemorrhage.

10 patients initiating therapy for PDR-related vitreous hemorrhage.

11 arance of floaters, along with a retinal and vitreous hemorrhage.

12 (adjusted for baseline VA) and clearance of vitreous hemorrhage.

13 rhegmatogenous retinal detachment along with vitreous hemorrhage.

14 Retinal and vitreous hemorrhage.

15 R), vitrectomy was resorted for non clearing vitreous hemorrhage.

16 relation between rivaroxaban and spontaneous vitreous hemorrhage.

17 agulation may be associated with spontaneous vitreous hemorrhage.

18 sk of retinal detachment in fundus-obscuring vitreous hemorrhage.

19 compared with observation alone in eyes with vitreous hemorrhage.

20 Forty-eight patients had bilateral vitreous hemorrhage.

21 of contraction-promoting growth factors, or vitreous hemorrhage.

22 Sequelae of LRV included vitreous hemorrhage (0.7%), retinal tears (2.8%), retina

23 adverse event from baseline to week 100 was vitreous hemorrhage (0.9% vs. 6.8% in the IAI 2Q4 + PRN

24 , temporary epithelial defect (1 [11%]), and vitreous hemorrhage (1 [11%]).

25 M (10 eyes), large exudative RD (4 eyes), or vitreous hemorrhage (1 eye).

26 age (1), central retinal vein occlusion with vitreous hemorrhage (1), and proliferative vitreoretinop

27 st frequent serious ocular adverse event was vitreous hemorrhage (1.3%, 0.7%, and 1.9%, respectively)

28 nts with epimacular proliferation (1.22) and vitreous hemorrhage (1.40) were also significantly eleva

29 quired vitreoretinal surgery for nonclearing vitreous hemorrhage, 1 in each 30 ms group; insignifican

30 se events were cataract (17.76%) followed by vitreous hemorrhage (12.10%) and retinal detachment (5.6

31 postoperative IVIs had a higher incidence of vitreous hemorrhage (18.5% vs. 3.2%, P = 0.039) than the

32 d at presentation; however, 8.0% of isolated vitreous hemorrhages, 19.2% of retinal breaks without de

33 More lasting complications included vitreous hemorrhage (2%), branch retinal artery obstruct

34 ed postmenstrual age (4 eyes, 30.8%); and/or vitreous hemorrhage (3 eyes, 23.1%).

35 resolving) included choroidal effusion (1), vitreous hemorrhage (3), Descemet detachment (1), and pe

36 66% (80%); neovascular glaucoma, 15% (22%); vitreous hemorrhage, 35% (42%); and secondary enucleatio

37 ma (8.9%), cystoid macular edema (6.9%), and vitreous hemorrhage (5.9%).

38 ion (5 eyes), and the development of a dense vitreous hemorrhage (6 eyes).

39 lar AESI; most common were cataract (11.4%), vitreous hemorrhage (6.1%), and conjunctival thickening

40 (9.1%, n=12), sterile vitritis (7.6%, n=10), vitreous hemorrhage (6.8%, n=9), choroidal detachment (3

41 5), sluggish pupil reactivity (6.9%, n = 4), vitreous hemorrhage (6.9%, n = 4), early hypofluorescenc

42 ses, 2 (0.8%) retinal detachments, 13 (5.2%) vitreous hemorrhages, 6 (2.4%) conjunctival erosions, an

43 to have PFV (49%), Coats' disease (20%), or vitreous hemorrhage (7%); those 2 to 5 years of age were

44 lications included IOL decentration (12.5%), vitreous hemorrhage (7.5%), IOL slippage (5%), IOL tilt

45 etinal detachment (12.5%), cataract (10.5%), vitreous hemorrhage (7.9%), and endophthalmitis (3.9%).

46 e (187.8), posterior capsule rupture (80.1), vitreous hemorrhage (76.9), and retinal detachment (20.8

47 most common postoperative complications were vitreous hemorrhage (8.2%, 0-41%), elevated intraocular

48 edema (14.4%), neovascular glaucoma (0.5%), vitreous hemorrhage (8.4%), and tractional retinal detac

49 Complications upon follow-up included vitreous hemorrhage (9 eyes), neovascular glaucoma (5 ey

50 Complications of PR included vitreous hemorrhage (9.1%), epiretinal membrane (45.17%)

51 While performing vitrectomy for severe vitreous hemorrhage, a point of strong adherence between

52 Three patients developed spontaneous vitreous hemorrhage after initiating rivaroxaban anticoa

53 ccurrence of a retinal tear, pre-retinal and vitreous hemorrhages after completing a session of whole

54 etic retinopathy in both eyes presented with vitreous hemorrhage and 6/60 visual acuity in his left e

55 rom a young boy with a history of idiopathic vitreous hemorrhage and a female infant with familial ex

56 These included vitreous hemorrhage and inflammatory or infectious findi

57 Physician treatment algorithms for diabetic vitreous hemorrhage and non-proliferative diabetic retin

58 biopsy can result in complications including vitreous hemorrhage and retinal detachment.

59 hole or epiretinal membrane), 1 patient had vitreous hemorrhage and the remaining 4 patients had rhe

60 complications other than cataract included 2 vitreous hemorrhages and 2 retinal detachments.

61 of retinal detachment, choroidal hemorrhage, vitreous hemorrhage, and disorganized intraocular conten

62 urgical time, early (<1 month) postoperative vitreous hemorrhage, and mean change in best-corrected v

63 (tractional retinal detachment, nonclearing vitreous hemorrhage, and neovascular glaucoma) and 111 c

64 ion retinopathy, radiation optic neuropathy, vitreous hemorrhage, and neovascular glaucoma) were anal

65 mplete vascularization of peripheral retina, vitreous hemorrhage, and persistence of massive intravit

66 s after implant surgery, including cataract, vitreous hemorrhage, and retinal detachment, were relati

67 ects, including endophthalmitis, retinal and vitreous hemorrhage, and retinal detachment.

68 ear [EY]), the 3 most common being cataract, vitreous hemorrhage, and retinal detachment.

69 in the growth of fragile new blood vessels, vitreous hemorrhage, and retinal detachment.

70 well as retinal/vitreous detachment, retinal/vitreous hemorrhage, and retinal tear (FAERS: ROR = 2.44

71 These can lead to retinal detachment, vitreous hemorrhage, and retinal toxicity.

72 included visual acuity, retinal detachment, vitreous hemorrhage, and secondary enucleation.

73 d to rule out vitreitis, retinal vasculitis, vitreous hemorrhage, and systemic amyloidosis.

74 ith NF1 and can cause exudative retinopathy, vitreous hemorrhage, and visual loss.

75 pathy, and concomitant retinal detachment or vitreous hemorrhage, and who were already on antidiabeti

76 In eyes with NVG, RVO and concurrent vitreous hemorrhage are risk factors for <=20/200 vision

77 In eyes with NVG, RVO and concurrent vitreous hemorrhage are risk factors for 20/200 vision a

78 ultivariable analyses identified presence of vitreous hemorrhage at baseline, increasing age, absence

79 Vitreous hemorrhage at presentation was associated with

80 Among eyes with vitreous hemorrhage at presentation, 42.0% had a concurr

81 Eyes without a vitreous hemorrhage at study entry were more likely to r

82 ck hours, number/size of breaks, presence of vitreous hemorrhage, axial length, or grade/extent of PV

83 who presented with nontraumatic, nonsurgical vitreous hemorrhage between 2002 and 2012 were reviewed.

84 Only 1 of 57 eyes (1.8%) showed a transient vitreous hemorrhage, biopsy yield was 100% for genetic a

85 oup, but rates of retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring

86 noblastomas include Coats' disease, PFV, and vitreous hemorrhage, but the spectrum varies depending o

87 baseline VA was worse than 20/800 and faster vitreous hemorrhage clearance.

88 cular hypertension, hemorrhagic retinopathy, vitreous hemorrhage, combined traction and rhegmatogenou

89 ults of the CT scan, to identify retinal and vitreous hemorrhages consistent with TS.

90 tachment, proliferative retinal disease, and vitreous hemorrhage contain varying amounts of growth fa

91 es with findings that would bias toward PPV (vitreous hemorrhage, dense cataract, proliferative vitre

92 Vitreous hemorrhage density was scored using a 0 to 4 vi

93 etween-group differences in the incidence of vitreous hemorrhage (DEX, 3 eyes [4%]; IVT, 1 eye [1%];

94 Consecutive patients with vitreous hemorrhage due to PDR undergoing primary vitreo

95 Consecutive patients with vitreous hemorrhage due to presumed posterior vitreous d

96 a randomized clinical trial among eyes with vitreous hemorrhage due to proliferative diabetic retino

97 The remaining 2 eyes had vitreous hemorrhage; endoscopic vitrectomy was done in t

98 glaucoma, macular edema, retinal detachment, vitreous hemorrhage, epiretinal membrane, and band kerat

99 edema, macular ischemia, foveal hemorrhage, vitreous hemorrhage, epiretinal membrane, and retinal de

100 Greater tumor thickness, vitreous hemorrhage, exudative retinal detachment, and p

101 our patient is the third documented case of vitreous hemorrhage following whole-body vibration train

102 safe and efficacious in preventing recurrent vitreous hemorrhage for PDR in the early postoperative p

103 d adults with vision loss due to PDR-related vitreous hemorrhage for whom vitrectomy was considered.

104 Vitreous hemorrhage from diabetic neovascularization rem

105 Study eyes had vitreous hemorrhage from PDR precluding panretinal photo

106 ed with vitrectomy) compared with saline for vitreous hemorrhage from PDR that precludes placement or

107 rate of vitrectomy by 16 weeks in eyes with vitreous hemorrhage from PDR.

108 including 205 adults with vison loss due to vitreous hemorrhage from proliferative diabetic retinopa

109 Among participants whose eyes had vitreous hemorrhage from proliferative diabetic retinopa

110 Vitreous hemorrhage from proliferative diabetic retinopa

111 hemorrhage density was scored using a 0 to 4 vitreous hemorrhage grading scale in 12 radial segments

112 Spontaneous pediatric vitreous hemorrhage has a diverse etiology, vasculitis b

113 Eyes with vitreous hemorrhage (hazard ratio [HR], 9.30; 95% confid

114 Compared with the reference group, vitreous hemorrhage (hazard ratio, 2.53 [P < 0.001] and

115 kin-8 and TNFalpha occurred in patients with vitreous hemorrhage; however, the only statistical diffe

116 t were associated with a lower occurrence of vitreous hemorrhages (HR, 0.74; 95% CI, 0.68-0.80), neov

117 or the secondary surgery included persistent vitreous hemorrhage in 1.9% (14/739), rhegmatogenous ret

118 n 15%, ocular hypertension in 10%, transient vitreous hemorrhage in 10%, retinal detachment in 5%, an

119 Postoperative complications included vitreous hemorrhage in 2 eyes, rhegmatogenous retinal de

120 ient ocular hypertension in 44 eyes (11.3%), vitreous hemorrhage in 31 eyes (7.9%), and transient hyp

121 permanent retinal detachment in 1 (7%), and vitreous hemorrhage in 4 (27%).

122 %), transient hypotony in 5 eyes (5.3%), and vitreous hemorrhage in 5 eyes (5.3%).

123 prescription (aDelta: -1.00, P = 0.024), and vitreous hemorrhage in at least 1 eye (aDelta: -1.92, P

124 d retinopathy of prematurity may suffer from vitreous hemorrhage in the absence of retinal tears, det

125 r RRDs occurred in 12.4% of patients who had vitreous hemorrhage, lattice degeneration, or a history

126 resence of lattice degeneration, presence of vitreous hemorrhage, location of retinal breaks, macular

127 acuity, lens status, presence or absence of vitreous hemorrhage, myopia, lattice degeneration, and s

128 embrane (n = 3), retinal hemorrhage (n = 2), vitreous hemorrhage (n = 1), retinal neovascularization

129 = 9) proliferative vitreoretinopathy (PVR), vitreous hemorrhage (n = 10), vitreous opacities (n = 8)

130 All eyes that had surgery for vitreous hemorrhage (N = 13) underwent PPV with endolase

131 hage (n = 3), preretinal hemorrhage (n = 1), vitreous hemorrhage (n = 2), and retinal tear (n = 1).

132 ina (n = 1); and had vitreous seeds (n = 3), vitreous hemorrhage (n = 2), retinal hemorrhage (n = 4),

133 stent fetal vasculature (PFV; n = 158; 28%), vitreous hemorrhage (n = 27; 5%), ocular toxocariasis (n

134 edema (n = 14 [8.6%]); retinal detachment or vitreous hemorrhage (n = 3 [1.9%]); posterior uveitis, r

135 etic tractional retinal detachment (n = 49), vitreous hemorrhage (n = 40), full-thickness macular hol

136 rhage (n = 38), cataract (n = 16), resolving vitreous hemorrhage (n = 6), and eye pain (n = 5).

137 ude misplaced gas injection, subretinal gas, vitreous hemorrhage, new retinal breaks, failure to reat

138 ect a significant difference in incidence of vitreous hemorrhage, NVI, NVG, or need for vitrectomy.

139 Postoperative vitreous hemorrhage occurred in 16 patients (44%), but a

140 Recurrent vitreous hemorrhage occurred within 16 weeks in 6% and 1

141 phics, visual acuity, cause of "spontaneous" vitreous hemorrhage, ocular and systemic findings at pre

142 regression analysis revealed the presence of vitreous hemorrhage (odds ratio [OR], 7.29; P < 0.001),

143 p, which was associated with RVO (P = .005), vitreous hemorrhage on presentation (P = .001), and no p

144 p, which was associated with RVO (P = .005), vitreous hemorrhage on presentation (P = .001), and no p

145 of retinal tears, extent of RRD, presence of vitreous hemorrhage or choroidal detachment, date and le

146 P < .001), pseudophakia (OR 1.25, P < .001), vitreous hemorrhage (OR 1.22, P = .001), and worse syste

147 III vs. I OR, 2.29 [1.53-3.41]; P < 0.0001), vitreous hemorrhage (OR, 2.29 [1.54-3.1]; P < 0.0001), a

148 vitreous pigment (OR, 57.0; CI, 39.7-81.7), vitreous hemorrhage (OR, 5.9; CI, 4.6-7.5), lattice dege

149 anretinal photocoagulation, (4) experiencing vitreous hemorrhage, or (5) undergoing vitrectomy for th

150 lar pressure (> 25 mmHg), hypotony, hyphema, vitreous hemorrhage, or endophthalmitis.

151 Patients with posterior injuries, vitreous hemorrhage, or poor presenting VA were more lik

152 The mass was presumed to be an organized vitreous hemorrhage originated from the optic disc.

153 ter injection was analyzed as a predictor of vitreous hemorrhage outcome at 3 months.

154 (p = 0.003), lens expulsion (p = 0.003) and vitreous hemorrhage (p < 0.001).

155 e tumor thickness (P = 0.01) and presence of vitreous hemorrhage (P = 0.05).

156 e (p = 0.555), macular hole (p = 0.695), and vitreous hemorrhage (p = 0.787).

157 ual improvement (p < 0.0001) had concomitant vitreous hemorrhage pre-op.

158 real aflibercept-based strategy for diabetic vitreous hemorrhage presents a 76% increased profit over

159 This study demonstrates that vitreous hemorrhage presumed secondary to PVD showed gre

160 he plan, history of nondiabetic retinopathy, vitreous hemorrhage, previous RD, or any other surgicall

161 retinal neovascularization, with subsequent vitreous hemorrhage, putatively through inflammatory mec

162 rgical procedure optimization, postoperative vitreous hemorrhage rate was 4.5% (7/157; 1 event classi

163 tion completion rates, and reduced recurrent vitreous hemorrhage rates suggest biologic activity of r

164 Complications (vitreous hemorrhage, retinal break, and retinal detachme

165 and development of fellow eye complications (vitreous hemorrhage, retinal break, and retinal detachme

166 curately coded (k = 0.61, 0.48, and 0.52 for vitreous hemorrhage, retinal detachment, and neovascular

167 tely coded (kappa = 0.61, 0.48, and 0.52 for vitreous hemorrhage, retinal detachment, and neovascular

168 (DR) and DR-related complications (including vitreous hemorrhage, retinal detachment, and neovascular

169 g outcome defined as the first occurrence of vitreous hemorrhage, retinal detachment, anterior segmen

170 ly was performed in patients with persistent vitreous hemorrhage, retinal detachment, lens dislocatio

171 gressive bullous retinoschisis, non-clearing vitreous hemorrhage, rhegmatogenous retinal detachment (

172 wound leaks, hypotony, choroidal detachment, vitreous hemorrhage, rhegmatogenous retinal detachment,

173 examination: preoperative PVR grade A or B, vitreous hemorrhage, RRD involving >= 50% of retinal are

174 in angiography (FA) following vitrectomy for vitreous hemorrhage secondary to PDR.

175 panretinal photocoagulation for nonclearing vitreous hemorrhage secondary to proliferative diabetic

176 Two months later, the vitreous hemorrhage spontaneously resolved and the patie

177 reases in local growth factor expression, or vitreous hemorrhage, suggesting that other mechanisms ar

178 ed and refined to help prevent postoperative vitreous hemorrhage using cryotherapy around sclerotomy

179 .006) in addition to presenting acuity, age, vitreous hemorrhage, uveal prolapse, and afferent pupill

180 ork Protocol S suggested that vitrectomy for vitreous hemorrhage (VH) or tractional retinal detachmen

181 dicting eyes that developed new or recurrent vitreous hemorrhage (VH) or tractional retinal detachmen

182 eal bevacizumab (IVB) use in patients with a vitreous hemorrhage (VH) secondary to proliferative diab

183 ) undergoing pars plana vitrectomy (PPV) for vitreous hemorrhage (VH) with IVB pretreatment were pros

184 underwent pars plana vitrectomy (PPV): 6 for vitreous hemorrhage (VH), 1 for epiretinal membrane (ERM

185 resence of fibrovascular proliferation (FP), vitreous hemorrhage (VH), and tractional retinal detachm

186 secondary outcome included incidence of PPV, vitreous hemorrhage (VH), or tractional retinal detachme

187 ng vitreoretinal surgeon for the presence of vitreous hemorrhage (VH), retinal tear (RT), retinal det

188 adverse visual outcomes including blindness, vitreous hemorrhage (VH), tractional retinal detachment

189 .79 versus 0.77 versus 1.20 (P < 0.0001) for vitreous hemorrhage (VH), vitreomacular interface abnorm

190 n (PRP) versus early vitrectomy for diabetic vitreous hemorrhage (VH).

191 proliferative diabetic retinopathy (PDR) and vitreous hemorrhage (VH).

192 A PPV was indicated in cases of nonresorbing vitreous hemorrhage (VH).

193 ons after first-eye PVD within 1 year (24.3% vitreous hemorrhage [VH], 24.1% retinal break [RB], 5.2%

194 Posttreatment vitreous hemorrhage, vitrectomy, and increased intraocul

195 rate of any complication was 25.0%, isolated vitreous hemorrhage was 13.1%, retinal breaks without de

196 the median time to clearance of the initial vitreous hemorrhage was 36 (interquartile range [IQR], 2

197 Vitreous hemorrhage was a risk factor for earlier retina

198 Permanent resolution of vitreous hemorrhage was achieved in 6 of 14 patients, an

199 Vitreous hemorrhage was associated with White race and i

200 Vitreous haze due to early recurrent vitreous hemorrhage was graded at weeks 1 and 4 as the m

201 detachment during the follow-up period, and vitreous hemorrhage was observed in 96.5% of cases (n =

202 ery and vitrectomy resulting from persistent vitreous hemorrhage was performed in 3.5% (n = 3) and 5.

203 nt ruptured globes, retinal detachments, and vitreous hemorrhages were excluded.

204 At initial presentation, vitreous hemorrhages were present in 22 eyes, hyphema in

205 with proliferative diabetic retinopathy and vitreous hemorrhage, where the highest concentrations of

206 Despite the presence of vitreous hemorrhages, which can possibly be avoided by o

207 ow a close association of a retinal tear and vitreous hemorrhage with whole-body vibration training.

208 Repeat retinal intervention for vitreous hemorrhage within 3 months was required in 5 of